LDOC1 (leucine zipper, down-regulated in cancer 1) by Hsiao, Jenn-Ren & Chang, Jang-Yang
Gene Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(1) 14 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
LDOC1 (leucine zipper, down-regulated in 
cancer 1) 
Jenn-Ren Hsiao; Jang-Yang Chang 
Department of Otolaryngology, Head, Neck Collaborative Oncology Group, National Cheng Kung 
University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; 
hsiaojr@mail.ncku.edu.tw (JRH); Department of Medicine, National Cheng Kung University 
Hospital, College of Medicine, National Cheng Kung University,, National Institute of Cancer 
Research, National Health Research Institutes, Tainan, Taiwan; E-mail: jychang@nhri.org.tw (JYC). 
Published in Atlas Database: December 2014 
Online updated version : http://AtlasGeneticsOncology.org/Genes/LDOC1ID41137chXq27.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62505/12-2014-LDOC1ID41137chXq27.pdf 
DOI: 10.4267/2042/62505
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
LDOC1 (leucine zipper, down-regulated in cancer 1) 
is expressed by a wide variety of normal human 
tissues but is downregulated in various kinds of 
human cancers. Epigenetic silencing by promoter 
hypermethylation was shown to be an important 
cause of LDOC1 down-regulation in oral, cervical 
and ovarian cancers. The normal physiological 
function of LDOC1 is still not clear. But the ability 
of LDOC1 to induce apoptosis in various kinds of 
human cancer cells suggests this gene may act as a 
tumor suppressor. 
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Identity 
Other names: BCUR1, Mar7, Mart7 
HGNC (Hugo): LDOC1 
Location: Xq27 
Location (base pair) 
starts at 141175745 and ends at 141177214 bp, 
complement 
Local order: from centromere to telomere: 
SPANXB1, LDOC1, SPANXC 
DNA/RNA 
Description 
The LDOC1 gene includes only one exon. 
Transcription 
A longer wild type 1376-bp transcript (Nagasaki et 
al., 1999), and a much shorter 165-bp splice variant 
LDOC1S (Duzakale et al. 2014) are reported.  
The cDNA sequence of wild type LDOC1 contains a 
104-bp 5' untranslated region (5'-UTR), a 438-bp 
open reading frame (ORF), and a 834-bp 3' 
untranslated region (3'-UTR) including a consensus 
polyadenylation signal (Nagasaki et al., 1999). 
Pseudogene 
Not reported. 
Protein 
Description 
The wild type LDOC1 is a 17 kDa protein containing 
146 amino acids, with a leucine-zipper like motif at 
the N-terminal and a proline-rich region that 
similarity to an Src homolog 3 (SH3)-binding 
domain (Nagasaki et al., 1999).  
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A shorter 165-bp splice variant is predicted to 
translate into a truncated protein of 44 amino acids 
that contains only the leucine-zipper region of wide 
type protein (Duzakale et al. 2014). 
Expression 
LDOC1 is expressed in a wide variety of normal 
tissues including heart, brain, lung, skeletal muscles, 
kidney, pancreas, spleen, thymus, prostate, testis, 
ovary, stomach, small intestine, colon, adrenal 
medulla, thyroid, adrenal cortex, thymus (Nagasaki 
et al., 1999). Down-regulation of LDOC1 have been 
reported in various kinds of human cancer tissues, 
including oral cancer (Lee et al., 2013), 
hepatocellular carcinoma (Riordan and Dupuy, 
2013), Chronic lymphocytic leukemia (Duzakale et 
al., 2014), prostate cancer (Camões et al., 2012), as 
well as in a variety of human cancer cell lines, 
including pancreatic cancer cell line, gastric cancer 
cell lines, some breast cancer cell lines (Nagasaki et 
al., 1999), ovarian cancer cell lines (Buchholtz et al., 
2014), cervical cancer cell lines (Buchholtz et al., 
2013) and oral cancer cell lines (Lee et al., 2013). 
Epigenetic silencing by promoter hypermethylation 
was shown to be an important cause of LDOC1 
down-regulation in oral cancer (Lee et al., 2013), 
cervical cancer (Buchholtz et al., 2013), and ovarian 
cancer cells (Buchholtz et al., 2014). 
Localisation 
LDOC1 localizes predominantly in the nucleus 
(Nagasaki et al., 1999). It may also be retained in 
cytoplasm through interaction with  WAVE3 
(Mizutani et al., 2005). 
Function 
Most reports demonstrated that the biological 
function of LDOC1 is closely related to modulation 
of apoptosis. Forced expression of LDOC1 induced 
apoptosis in Jurkat lymphoma cells, K562 leukemia 
cells (Inoue et al., 2015), Hela cervical cancer cells 
(Buchholtz et al., 2013) and oral cancer cells (Lee et 
al., 2013). Expression of LDOC1 also enhanced 
TNF-a or phorbol 12-myristate 13-acetate (PMA)-
induced anti-proliferative effects in pancreatic 
cancer cells (Nagasaki et al., 2003). A hematopoietic 
transcriptional factor (MZF-1) important in 
regulating myeloid cell differentiation and 
proliferation may interact with LDOC1 and enhance 
it apoptosis-inducing function in K562 leukemia 
cells (Inoue et al., 2015). LDOC1 also induced 
apoptosis and inhibited degradation of p53, resulting 
in p53 accumulation in MDCK cells. WAVE3 could 
interact with LDOC1 with its C-terminal verprolin 
homolog domain and act as a negative regulator of 
LDOC1. Forced expression of WAVE3 retained 
LDOC1 in cytoplasm and attenuated the apoptosis-
inducing effect of LDOC1 (Mizutani et al., 2005). 
Expression of LDOC1 also significantly inhibited 
the NF-kB reporter activity in LDOC1-negative 
BxPC-3 pancreatic cancer cells (Nagasaki et al., 
2003) and suppressed TNF-a induced activation of 
NF-kB (Lee et al., 2013). LDOC1 may also interact 
with CCAAT-enhancer binding protein-a (C/EBPa) 
(Chih et al., 2004). However, in human intrahepatic 
biliary epithelial cells, over expression LDOC1 
increased the expression of NF-kB (p65), promoted 
IL-2 and TNF-a secretion and inhibited apoptosis 
(Song et al., 2013). LDOC1 has recently been 
reported as a eutherian-specific acquired gene that 
regulates placental endocrine function (Naruse et al., 
2014). 
Homology 
HomoloGene:32153 
Implicated in 
Chronic lymphocytic leukemia 
Prognosis 
Expression of LDOC1 mRNA correlated with 
prognostic cytogenetic markers of chronic 
lymphocytic leukemia patients. In primary patients, 
LDOC1 mRNA-positive group of patients had 
significantly poorer overall survival compared to 
LDOC1 mRNA-negative group of patients 
(Duzakale et al., 2014). 
Lymphoma 
Oncogenesis 
Forced expression of LDOC1 induced apoptosis in 
Jurkat lymphoma cell lines (Inoue et al., 2015). 
Leukemia 
Oncogenesis 
Forced expression of LDOC1 induced apoptosis in 
K562 leukemia cell lines (Inoue et al., 2015). 
Ovarian cancer 
Cytogenetics 
No gene deletion was detected in the 7 ovarian 
cancer cell lines. 
Oncogenesis 
Three of the 7 ovarian cancer cell lines showed 
complete loss of LDOC1 transcription, which may 
due to hypermethylation and inactivation of LDOC1 
promoter. Treatment of de-methylation agent (5-aza-
2'-deoxycytidine) on ovarian cancer cells induced 
transcriptional reactivation of LDOC1 gene 
(Buchholtz et al., 2014). 
Cervical cancer 
Cytogenetics 
No gene deletion was detected in the 6 cervical 
cancer cell lines. 
Oncogenesis 
LDOC1 was silenced in 4 of the 6 cervical cancer 
cell lines. An association of promoter 
hypermethylation and gene silencing was noted. 
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Reactivation of LDOC1 gene was noted in Me180 
and SiHa cervical cancer cell lines by demethylation 
agent treatment (5-aza-2'-deoxycytidine). Re-
expression of LDOC1induced apoptosis-like cell 
death in Hela cervical cancer cells (Buchholtz et al., 
2013). 
Oral cancer 
Oncogenesis 
Hypermethylation and down-regulation of LDOC1 
were consistently noted in oral cancer samples and 
oral cancer cell lines. Reactivation of LDOC1 gene 
was noted in oral cancer cells by demethylation 
agent treatment (5-aza-2'-deoxycytidine). Re-
expression of LDOC1suppressed TNF-a induced 
activation of NF-?B and suppressed the colony 
forming and in vivo tumorigenic abilities of oral 
cancer cells. Epigenetic silencing of LDOC1 may 
contribute to alcohol, betel quid and smoking-
associated oral carcinogenesis (Lee et al., 2013). 
Prostate cancer 
Oncogenesis 
LDOC1 was one of the two transcriptional units 
(LDOC1, HPANXC) mapped in a critical region of 
HPCX locus linked to prostate cancer susceptibility 
in Finland (Baffoe-Bonnie et al., 2005). In addition, 
compared to non-malignant prostate tissue, LDOC1 
was under-expressed (1.8 fold decrease) in prostate 
cancer tissues, although no methylation of LDOC1 
promoter was noted in prostate tumor samples 
(Camões et al., 2012). 
Hepato cellular carcinoma 
Oncogenesis 
LDOC1 was downregulated in 60% (29/48) of 
hepatic cellular carcinoma samples compared to 
adjacent non-tumor liver tissues (Riordan and 
Dupuy, 2013). 
Pancreatic cancer 
Oncogenesis 
Down-regulation of LDOC1 was noted in 8 of 9 
pancreatic cancer cell lines except CAPAN2 cell line 
(Nagasaki et al., 1999). LDOC1 was expressed in 
normal pancreatic tissue (Nagasaki et al., 2003). 
Expression of LDOC1 significantly inhibited the 
NF-kB reporter activity but does not affect p53, AP1 
and CRE-dependent reporter gene expression in 
LDOC1-negative BxPC-3 pancreatic cancer cell 
line. LDOC1 also enhanced TNF-a or phorbol 12-
myristate 13-acetate (PMA)-induced anti-
proliferative effects in pancreatic cancer cells 
(Nagasaki et al., 2003). 
Gastric cancer 
Oncogenesis 
Using northern blot, down-regulation of LDOC1 
was noted in 6 (100%) of 6 gastric cancer cell lines. 
LDOC1 was normally expressed in stomach tissue 
(Nagasaki et al., 1999). 
Lung cancer 
Oncogenesis 
LDOC1 was differentially expressed in MASPIN-
overexpression lung carcinoma cells (LC5) 
compared to MASPIN-knockdown LC5 cells (Liu et 
al., 2012). 
Esophageal cancer 
Oncogenesis 
LDOC1 was down-regulated in a radio-sensitive 
esophageal cancer cell line (TE-11) compared to 
other relative radio-resistant esophageal cancer cell 
lines (Ogawa et al., 2008). 
Cutaneous malignant melanoma 
Oncogenesis 
LDOC1 was downregulated in peripheral blood 
leukocytes from a cutaneous malignant melanoma 
patient with multiple in-transient metastases, 
compared to 3 normal controls (Salemi et al., 2010). 
Hypertension 
LDOC1 gene was consistently influential in a three-
endophenotype model for Taiwanese hypertensive 
males (Lynn et al., 2009). 
Premature ovarian 
failure/insufficiency (POF/POI) 
Array comparative genomic hybridization identified 
a cryptic deletion region of Xq27.2 containing 
LDOC1 and SPANX genes in a 23-year old woman 
with premature ovarian failure/insufficiency (Vitek 
et al., 2012). 
Down's syndrome 
Gene expression of LDOC1 was increased in 
peripheral blood leukocytes from 15 (75%) of 20 
patients Down's syndrome, as compared to that of 20 
age-, sex-matched normal controls (Salemi et al., 
2012). 
Biliary atresia 
Over expression LDOC1 in human intrahepatic 
biliary epithelial cells increased the expression of 
NF-kB (p65), promoted IL-2 and TNF-a secretion 
and inhibited apoptosis of human intrahepatic biliary 
epithelial cells, which may induce intrahepatic 
biliary epithelial cell hyperplasia and trigger biliary 
atresia, bile duct stenosis and hepatic fibrosis (Song 
et al., 2013). 
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